22/3 - 2017

Pelago celebrates 4 years of success. Read more here or simply click on the image to open the full PDF.

16/1 - 2017

Today is the first day of our new collaboration with CBCS at the Karolinska Institute to accelerate the development of high throughput CETSA assays: lcbkipelagopr.pdf

13/1 - 2017

Pelago Bioscience is now collaborating with Sygnature Discovery. The press release on the new offer from Pelago and Sygnature can be read here: sygnaturepelago.pdf

20/12 - 2016

1 av 3 får cancer. Men alla drabbas. Vårt företag vill ändra på det och därför stödjer vi Cancerfonden som Företagsvän 2016. Tillsammans kan vi besegra cancer! #cancerfonden

11/10 - 2016

Open House Quiz winner! 

On Wednesday September 28th, Pelago arranged an Open House for collaborators, customers, suppliers and company friends.

We are proud to present the winner of our Quiz walk: Anna Bogstedt. Congratulations Anna for your outstanding Pelago knowledge!

12/9 -2016

Read about our new collaborations, publications and other hot topics at Pelago, click on the image or here to open the full PDF.

8/9 - 2016

Pelago coauthors, together with Astra Zeneca and University of Sheffield, a study in Nature Chemical Biology where CETSA was instrumental in proving cellular target engagement of compounds targeting Fen-1.

Here is a link to Nature Chemical Biology and the article

1/8 - 2016

The WuXi App Tec collaboration ( is announced today by a press release: wuxiapptecsresearchservicedivisioncollaborateswithpelagobiosciencetoprovidecetsabasedtargetengagementassays.pdf 

13-14/6 - 2016

17th Drug Discovery Summit and 4th Discovery Chemistry & Drug Design Congress in Berlin. Meet us at: ddx_summit17_berlin.pdf

8/6 - 2016

Pelago will be present at this years Biotech Hanse Forum. The Biotech Hanse Organisation aims at connecting people from the biotech and life-science sectors of Sweden and Germany. Read more here

31/5 - 2016

Pelago Bioscience will attend the Astra Zeneca Exchange meeting in Mölndal.

18-19/5 - 2016

Pelago will be at the 9th Global Discovery to Development Innovation Forum in London. Find out more here

9/5 - 2016

CETSA® and Pelago explained in 8 minutes:

16/4 - 2016

The CEO and CSO of Pelago Bioscience will attend the AACR meeting, this year in New Orleans, April 16-20th. Come visit our poster (#354)! Also, the inventor of the CETSA method, Pär Nordlund, will give a talk in the ”New ’cool tools’ for Cancer Discovery” session. Find out more about the conference here

4/4 - 2016

Pelago Bioscience will attend the premier partnering conference BIO-Europe Spring®, which takes place in Stockholm April 4-6. The event attracts large pharma and biotech companies, innovative startups and financiers, basically all companies represented across the life science value chain. Find out more here

24/3 - 2016

Pelagos CSO Daniel Martinez Molina and Pär Nordlund co-authors the first CETSA® HT screening paper, identifying novel binders of Thymidilate Synthase. You will find the publication here.

8/3 - 2016

Pelago Bioscience will attend the 2nd Oncology Strategy Meeting Europe 2016 in London, March 8-9. Find out more from the programme here.

8/1 - 2016

The inventor of CETSA® and co-founder of Pelago: Prof Pär Nordlund will be a plenary speaker at the upcoming Structure Based Drug Design Conference 2016February 21-24th in San Diego. Have a look at the programme here

10/12 - 2015

This year we are very proud and happy to donate our christmas gift to Min Stora Dag/My Special Day - a foundation who give special kids great memories. Merry Christmas!

27/11 - 2015

Our new strategic collaboration with AstraZeneca will further accelerate the development of CETSA® applications relevant for drug discovery. pressreleasepelagoaz.pdf

23/11 - 2015

We have together with Karolinska Universitetssjukhuset been awarded a SWELife/Vinnova grant to start exploring CETSA® as an In Vitro Diagnostic tool in the validation of predictive biomarkers. swelifegrantpressrelease.pdf

13/10 - 2015

Pfizer Inc. and Pelago annouce that we have entered in to a sub-licensing agreement on the use of the CETSA™ method. Read the full statement here: pressreleasepbpfizer.pdf

7/9 - 2015

Pelago and Biovica announce our collaboration to develop a novel platform to enable development of novel oncology drugs: press-release

30/7 - 2015

Pelago customer Sprint Bioscience have announced a commercial and collaborative agreement with Bayer HealthCare on R&D and commericialisation of Sprint's MTH1 inhibitor programme. Under the agreement Sprint will outlicense their MTH1 programme in return for an upfront payment of a couple of millions EUR and up to 190 mill EUR in milestone related payments.

10/6 - 2015

We announce the new commercial and scientific collaboartion with OmicScouts on CETSA™ mass spec applications. Read the full press release here: pressreleaseos_pb_150610.pdf.

10/5 - 2015

CETSA™ inventor Professor Pär Nordlund will present drug discovery relevant research using the method at the 2nd NovAliX Conference 2015 in Strassbourg June 9-12th.

12/3 - 2015:

The CETSA™ method is now patented in the US under patent number 8,969,014.

26/2 - 2015

Pelago Bioscience will present at the Karolinska Institutet Science Park Day 2015. See the full programme and register here: KISP Day 2015

16/12 - 2014

Professor Nordlund, CETSA inventor and Pelago Bioscience co-founder will give a talk at the 
12th Winter Conference of Medicinal and Bioorganic Chemistry 25-29/1 2015 entitled: Monitoring Target Engagement using the Cellular Thermal Shift Assay for Lead Drug Development, Drug Deorphanization and Off-Target Studies

17/11 - 2014

Pelago Bioscience CEO Michael Dabrowski will participate in the Genesis 2014 conference in London, December 9th.

3/11 - 2014

OnTarget is the CETSA™ service distributor in Japan

3/10 - 2014

CETSA and mass spectometry combined to revolutionize biomarker and target identification published in Science